November 23, 2021SHILAP Revista de lepidopterología63 citationsOpen Access

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis

YXYuanfang XinQinghai Red Cross Hospital GSGuoshuang ShenQinghai University YZYong‐Hui ZhengHarbin Medical University

Key Points

Key points are not available for this paper at this time.

Abstract

PD-1/PD-L1 inhibitors combined with chemotherapy can improve pCR rates and EFS, and with an increased incidence of some immune-related AEs compared with chemotherapy alone. NACT plus ICIs might be an option in patients with in PD-L1 positive and high-risk populations with positive nodal disease early TNBC.

KI fragen

Bookmark

View Full Paper

Cite This Study

Xin et al. (Tue,) studied this question.

synapsesocial.com/papers/69dcf8eb7d2a65005be52d1f https://doi.org/https://doi.org/10.1186/s12885-021-08997-w

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper